performed to either DCB application or no further treatment. Provisional stenting was discouraged but allowed in both groups. Follow-up angiograms were done after 9 months. For quantitative coronary angiographic analysis CAAS II was used. Primary efficacy endpoint was late lumen loss (LLL). Results: 64 patients were randomized to DCB or POBA treatment. Minimal lumen diameter (0.58 AE 0.22 mm) and grade of stenosis (76.3 AE 8.7 %) were equal in both groups. Only 5 stents were used as bail out. Angiographic follow-up was achieved in 75 % of patients. The remaining 25 % had telephone follow-up. No patient was lost to follow-up, no patient died. There was 1 non ST-elevation myocardial infarction in the POBA group. Restenosis rate was 25 % in the POBA group vs. 6 % in the DCB group (p¼0.08). Target lesion revascularization was necessary in 3 patients of the POBA vs. 1 patient of the DCB group. The primary endpoint LLL was 0.15 mm in the DCB vs. 0.48 mm in the POBA group (p¼0.035). Conclusions: Our results underscore the potential of DCBs as stand alone therapy for bifurcation lesions. Therefore, in bifurcation lesions that show only class A or B dissection according to the NHLBI classification and recoil not beyond 30 % the use of DCBs is a sound strategy.
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Background: Paclitaxel-coated balloons (PCB) have been proven to be effective for the treatment of coronary in-stent restenosis (ISR) after bare-metal stent (BMS) or drug-eluting stent (DES) implantation. This study aims to evaluate the long-term safety and efficacy of the second-generation SeQuent Please PCB in coronary ISR in routine real-world practice. Methods: Between May 2009 and February 2011, all consecutive patients with ISR lesions treated with the SeQuent Please PCB at our institution were prospectively included. Patients were followed up for 36 months by clinical observation. The primary endpoint was the clinically driven target lesion revascularization (TLR) rate at 36 months. The secondary endpoint was the rate of major adverse cardiac events (MACE: defined as a composite of cardiac death, myocardial infarction, and TLR) at 36 months. Results: 63 patients with 73 ISR lesions (39 BMS, 34 DES) were included. Mean age was 67.4AE11.7 years. 77.8 % were male and 55.6 % were diabetics. The majority of patients presented with stable angina (61.9 %). The target lesion was mainly located in the right coronary artery (42.5%) and the left anterior descending coronary artery (38.4%). The mean reference vessel diameter was 3.0AE0.5 mm and the mean target lesion length was 19.7 AE 6.6 mm. Procedural success was 100 %. Coronary dissection occurred in 2 patients (3.2 %), requiring additional stent implantation. Follow-up rate was 92.1 %. The TLR rate was 4.8 % after 36 months. Cumulative MACE at 36 months was 11.1 %, with 4.8 % cardiac death and 3.2 % myocardial infarction. No vessel thrombosis was documented. The TLR rate did not differ for PCB angioplasty for BMS-ISR compared with DES-ISR (2.9 % vs. 7.1%, p¼0.58). Baseline lesion characteristics and procedural data did not differ except for a longer lesion length for BMS-ISR compared with DES-ISR (21.7AE6.0 mm vs. 17.3AE6.5 mm, p¼0.004). Conclusions: Treatment of coronary ISR with the second-generation SeQuent Please PCB provides good clinical outcomes demonstrated by the low TLR rate and low MACE rates at long-term follow-up.
TCT-287
Safety Evaluation of Paclitaxel Coated Balloon as a "Same-Drug" and "Crossover-Drug" Treatment for Drug Eluting Coronary Stent In-Stent Restenosis in a Large Animal Model Serge D. Rousselle 1 , Yan Li 2 , Chris Barry 2 , Javier A. Garza 1 , Armando Tellez 1 1 Alizée Pathology, LLC, Thurmont, MD, 2 Lutonix, Inc, New Hope, MN Background: DES in-stent restenosis (ISR) is a more complex issue compared to BMS-ISR. Paclitaxel coated balloons (PCB) are available as an option for DES-ISR treatment. We aim to evaluate the vascular response to Lutonix PCB as treatment of a same drug DES-ISR (Paclitaxel) and cross-over drug DES-ISR (-Limus) in a large animal coronary ISR model. ; PES/PCB [T6]) treatment and they were followed for additional 30 days. Morphometry and safety parameters were assessed by histopathology by a semiquantitative score (0¼ not present-4¼overwhelmingly present). Results: DCB treatment groups display a similar larger lumen area (T1¼5.8AE3.2mm; T2¼6.3AE2.6mm; T3¼6.1AE1.3) compared to POBA treatment (T4¼5.4AE3.3mm; T5¼6.1AE2.8mm; T6¼5.9AE2.4mm). Neotintimal area was reduced in the DCB treatment group (T1¼2.9AE0.8; T2¼2.6AE1.3; T3¼3.2AE2.2) compared to POBA groups (T4¼3.9AE2.1; T5¼4.1AE2; T6¼3.9AE3.5). In histology, similar degree of inflammation was observed among PCB treatment groups (T1¼1.9AE1.5; T2¼1.3AE1.1; T3¼1.9AE1.7) compared to a slight higher inflammatory scores in the POBA treatment groups (T4¼2AE1; T5¼1.8AE1.2; T6¼2.2AE1). Fibrin deposition was low in all groups (T1¼0.9AE0.4; T2¼0.6AE0.3; T4¼0.7AE0.9; T5¼0.4AE0.5), however when PES was used the fibrin score was slightly higher (T3¼1.3AE0.9; T6¼1AE0.5). Complete endothelial coverage was observed in all treated groups (T1¼3.5AE0.4; T2¼3.8AE0.5; T3¼3.33AE0.8; T4¼3.75AE0.3; T5¼4AE0; T6¼3.9AE0.2). The neointima hypocellularity was assessed showing a similar low score (T1¼1AE0.86; T2¼0.5AE0.8; T3¼1.5AE1; T4¼0.6AE1.2; T5¼0AE0; T6¼1AE0.3). All treatment groups showed an extremely low thrombosis score (T1¼0.1AE0.2; T2¼0AE0, T3¼0.2AE0.3; T4¼0.1AE0.2; T5¼0AE0; T6¼0AE0). Conclusions: Lutonix PCB, in a "cross-over" or "same drug" treatment, seem to be a safe strategy for DES-ISR without significantly increasing inflammation or fibrin deposition in a large animal preclinical model.
TCT-288
First in Vivo Evaluation of Efficacy of a Novel Peripheral Drug-Coated Balloon in a Familial Hypercholesterolemic Swine Model of In-Stent Restenosis Carlos A. Gongora 1 , Masahiko Shibuya 1 , Barbara A. Huibregtse 2 , Jenn McGregor 1 , Yanping Cheng 1 , Gerard B. Conditt 1 , Geng-Hua Yi 1 , Greg L. Kaluza 1 , Juan Granada 1 1 Cardiovascular Research Foundation, Orangeburg, NY, 2 Boston Scientific, Marlborough, MA Background: Drug coated balloons (DCBs) employ different coating technologies to deliver the antirestenotic drug without permanent polymer carrier. The ideal formulation should maximize the neointimal inhibition with the least drug possible, while ensuring adequate healing and containing the particulate release from the coating. We evaluated the efficacy of a novel drug coated balloon technology with two clinically proven DCBs and an uncoated balloon control group in a familial hypercholesterolemic swine (FHS) model. Methods: Twenty four peripheral arteries of 6 FHS were injured at day 0 with an uncoated balloon, followed by implantation of self-expanding stents in the injured segments. At day 14, the in-stent restenosis sites were treated with two clinically proven DCB (In.PactÔ Pacific Medtronic , 3 ug/mm2 n¼6), and (LutonixÔ BARD, 2 ug/mm2 n¼6), a novel DCB (RangerÔ Boston Scientific, 2 ug/mm2 n¼6), and an uncoated balloon control (SterlingÔ, Boston Scientific, n¼6) . At day 0, 14 and 42 quantitative vascular analysis and histology at terminatio. Results: The difference (D) in angiographic percentage diameter stenosis between day 14 and day 42 showed significant inhibition of neointimal proliferation with smaller deltas from baseline in the DCB groups when compared to control (Control: D60%, Ranger: D10%, InPact: D5%, Lutonix: D10%). The histological data also showed less neointima and percentage area of stenosis in all DCB groups. Fibrin, a characteristic hallmark of paclitaxel in arterial tissue, was equivalent in all DCBs and twice as high as in control. Ranger DCB showed a slightly higher endothelialization score than In.Pact (Control: 3AE0, Ranger: 2.57AE0.34, In.Pact: 1.85AE0.55, Lutonix: 2.52AE0.35, p¼< 0.05), and In.Pact had the lowest score of neointima maturity (Control: 2.9AE0.11, Ranger: 1.87AE0.66, In.Pact: 1.48AE0.74, Lutonix: 1.88AE0.49, p¼< 0.05). Conclusions: All DCBs showed significant inhibition of neointimal formation when compared to the uncoated balloon control. The In.Pact DCB provided strongest neointimal inhibition but less complete healing. The Ranger DCB provided satisfactory neointimal inhibition and a slightly better healing when compared to In.Pact.
TCT-289

Detection of Paclitaxel Contamination Resulting from the Simulated Clinical Use of Drug Coated Balloon Catheters
Charisse Ward 1 , Carlos I. Mena 1 1 Yale University, New Haven, CT Background: Coating robustness and durability are important characteristics of the DCB design. Drug that is not firmly adhering on the balloon surface falls off and could potentially lead to paclitaxel contamination of work surfaces in the catheterization lab and expose lab personnel to a toxic chemotherapeutic agent. Methods: This study sought to determine the coating durability of the Lutonix drug coated balloon compared to the Medtronic drug coated balloon and to evaluate the amount of paclitaxel that does not adhere to the balloon and is transferred to work surfaces during simulated clinical procedural handling. A swab method in the Che-moGLOÔ kit was used for quantifying trace amount of drug on surface. Both the Medtronic devices and the Lutonix devices were evaluated in a simulated clinical use study by three independent physicians at three hospitals. After each physician performed the simulated clinical use test, the surfaces where paclitaxel could have fallen were swabbed and analyzed for paclitaxel by HPLC (LLQ is 0.01ng/cm2.) The person performed the swabbing was blinded to the testing devices. Results: The paclitaxel analysis results from this study and statistical analysis are summarized on table 1.The ANOVA analysis indicates that paclitaxel surface concentrations of the Lutonix devices and the Medtronic devices are statistically different.
Conclusions:
This study revealed 15 out of 18 Medtronic devices were over the decontamination level, none of the 21 Lutonix devices was over the decontamination level. Precautions to avoid working place drug contamination may be required for handling the Medtronic drug coated balloon catheters. Drug decontamination is recommended after each time use of the Medtronic DCB catheters to ensure the drug surface concentration is below 1ng/cm2. 
Devices
